<DOC>
	<DOCNO>NCT01870908</DOCNO>
	<brief_summary>This study evaluate safety effectiveness treatment tacrolimus biological agent .</brief_summary>
	<brief_title>Special Drug Use-Results Survey Prograf Capsule Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The purpose study confirm safety 24 weeks-treatment combination tacrolimus + biological agent , ass efficacy use SDAI , CDAI , DAS28-CRP , MMP-3 , MHAQ patient rheumatoid arthritis achieve SDAI remission despite use biological agent 8 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>patient rheumatoid arthritis treat biological agent 8 week achieve SDAI remission ( SDAI &lt; 3.3 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>